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INTRODUCTION
Removal of colorectal adenomas during colonoscopy has 
been shown to reduce the risk of future colorectal cancer 
(CRC) and advanced adenomas. To further minimize the 
risk of CRC, surveillance with colonoscopy is recommended 
after the detection and removal of colonic neoplasia. In the 
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Background/Aims: Colonoscopic surveillance is currently recommended after polypectomy owing to the risk of newly de-
veloped colonic neoplasia. However, few studies have investigated colonoscopy surveillance in Asia. This multicenter and pro-
spective study was undertaken to assess the incidence of advanced adenoma based on baseline adenoma findings at 3 years 
after colonoscopic polypectomy. Methods: A total of 1,323 patients undergoing colonoscopic polypectomy were prospectively 
assigned to 3-year colonoscopy surveillance at 11 tertiary endoscopic centers. Relative risks for advanced adenoma after 3 
years were calculated according to baseline adenoma characteristics. Results: Among 1,323 patients enrolled, 387 patients 
(29.3%) were followed up, and the mean follow-up interval was 31.0±9.8 months. The percentage of patients with advanced 
adenoma on baseline colonoscopy was higher in the surveillance group compared to the non-surveillance group (34.4% vs. 
25.7%). Advanced adenoma recurrence was observed in 17 patients (4.4%) at follow-up. The risk of advanced adenoma recur-
rence was 2 times greater in patients with baseline advanced adenoma than in those with baseline non-advanced adenoma, 
though the difference was not statistically significant (6.8% [9/133] vs. 3.1% [8/254], P=0.09). Advanced adenoma recurrence 
was observed only in males and in subjects aged ≥50 years. In contrast, adenoma recurrence was observed in 187 patients 
(48.3%) at follow-up. Male sex, older age (≥50 years), and multiple adenomas (≥3) at baseline were independent risk factors for 
adenoma recurrence. Conclusions: A colonoscopy surveillance interval of 3 years in patients with baseline advanced adeno-
ma can be considered appropriate. (Intest Res 2018;16:126-133)
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past, it was common practice to perform annual follow-up 
surveillance colonoscopies in patients with colorectal ad-
enomas in order to detect newly developed metachronous 
adenomas and missed synchronous adenomas.1 However, 
most patients with colorectal adenoma experience no ben-
efit from surveillance and only 6% develop CRC,2 suggest-
ing that, ideally, surveillance should be targeted at patients 
most likely to develop CRC. Several studies have found that 
certain adenoma characteristics at baseline colonoscopy 
are associated with the rate of adenoma detection and the 
histologic severity of subsequent adenomas during surveil-
lance.3,4 Patients with multiple adenomas or adenomas with 
advanced pathological features at baseline have been found 
to have an increased risk of developing CRC.4,5 
Current Western guidelines have recommended colonos-
copy surveillance intervals according to the risk stratification 
of patients based on the findings at baseline colonoscopy.6 
According to U.S. guidelines, surveillance colonoscopy 
should be repeated at 10 years for patients with no neoplasia 
at baseline, at 5 to 10 years for low-risk patients with 1 or 2 
small (<10 mm) tubular adenomas, and at 3 years for high-
risk patients with advanced neoplasia or more than 2 adeno-
mas.7 However, to date, few studies have evaluated colonos-
copy surveillance after polypectomy in Asia.8
The aims of this prospective and multicenter study were 
to determine the 3-year cumulative incidence rate of ad-
vanced neoplasia in Korean patients with baseline colorectal 
neoplasia at screening colonoscopy and to determine which 
baseline colonoscopic findings are associated with the re-
currence of advanced neoplasia.
METHODS
1. Study Population
Participants were enrolled in 11 University Hospitals be-
tween March 2007 and December 2008. The study protocol 
was approved by the Institutional Review Boards of each 
participating center. Written informed consent for participa-
tion was obtained from all participants prior to the proce-
dures. Initial enrollment criteria included individuals who 
did not have lower gastrointestinal tract symptoms, prior 
history of colon disease, or structural examination of the co-
lon within 10 years. Patients were eligible if they underwent 
a complete colonoscopy and were found to have 1 or more 
adenomas at baseline colonoscopy. A complete colonos-
copy was considered to include the following: good bowel 
preparation, colonoscopy reaching the cecum, and removal 
of all visualized polyps that were detected. Patients were ex-
cluded if baseline colonoscopy revealed invasive CRC (can-
cer invading beyond muscularis mucosa), nonadenomatous 
polyps, IBD, or familial adenomatous polyposis.
At enrollment, patients were interviewed to assess the 
following data: age; gender; family history of CRC; current 
smoking and alcohol consumption; history of diabetes and 
hypertension; use of medications including aspirin, NSAIDs, 
and statins.
All enrolled patients were assigned to colonoscopy surveil-
lance at 3 years. Follow-up clinic reminder calls were made 
several months before the expected date of colonoscopy 
surveillance from each participating center.
2. Colonoscopy and Pathological Review
All colonoscopic examinations were performed by study 
investigators. During baseline and surveillance colonoscopy, 
the characteristics of all detected polyps including number, 
size, and location were identified. The size of the polyp was 
estimated with an opened biopsy forceps. The location of 
the polyp was categorized as proximal (cecum, ascending 
colon, hepatic flexure, transverse colon, and splenic flexure) 
or distal (descending colon, sigmoid colon, and rectum). All 
detected polyps were completely removed; diminutive pol-
yps were removed by ≤5 mm by biopsy forceps and larger 
ones by colonoscopic polypectomy or endoscopic mucosal 
resection. All specimens were evaluated by local expert gas-
trointestinal pathologists according to the colorectal neopla-
sia classification of the World Health Organization (WHO) 
recommendations.9
Pathological interpretation of intramucosal carcinoma or 
carcinoma in situ was categorized as a high-grade dysplasia. 
Invasive cancer was defined as the invasion of malignant 
cells beyond the muscularis mucosa. In patients with mul-
tiple adenomas, the size, location, and histological type were 
classified according to the largest, the most proximal, and the 
most advanced lesion, respectively. Advanced adenoma was 
defined as tubular adenoma 10 mm or larger in diameter, vil-
lous or tubulovillous adenoma, or adenoma with high-grade 
dysplasia.
3. Statistical Analysis
We compared the baseline demographic and adenoma 
characteristics of subjects who underwent follow-up colo-
noscopy with those of subjects who did not using the Stu-
dent t -test and chi-square test as appropriate for the com-
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parison of means and proportions. The RR of recurrence of 
advanced adenoma and any adenoma were estimated using 
the Cox proportional hazard regression model by comput-
ing the hazard ratio and the 95% CI after multivariate adjust-
ments (demographic and baseline adenoma characteristics). 
Statistical analyses were performed using SPSS version 12.0 
for Windows (SPSS Inc, Chicago, IL, USA). A two-sided value 
of P<0.05 was considered statistically significant.
RESULTS
1. Baseline Characteristics of the Study Population
A total of 1,323 patients with colorectal adenoma at 
baseline colonoscopy were enrolled and assigned to colo-
noscopy surveillance at 3 years. During surveillance, 29.3% 
of patients (387/1,323) had a surveillance colonoscopic 
examination, and the mean follow-up interval was 31.0±9.8 
months. We compared the baseline demographic and ad-
enoma characteristics of the surveillance group with those 
of the non-surveillance group to determine whether there 
were any differences in the possible risk factors for advanced 
colorectal neoplasia between the 2 groups (Table 1). There 
were no significant differences in terms of age, family history 
of CRC, co-morbidities (hypertension and diabetes), and use 
of medications (aspirin, NSAIDs, and statins). However, the 
surveillance group had higher proportions of males, smok-
ers, and alcohol drinkers, and was more likely to have pur-
ported high CRC risk variables of baseline adenoma includ-
ing advanced adenoma, number, size, and villous histology. 
Accordingly, we analyzed the incidence and risk factors of 
colorectal adenoma recurrence in the surveillance group.
Table 1. Baseline Demographic and Adenoma Characteristics of the 
Enrolled Patients
Surveillance 
group
Non-surveillance 
group P-value
Number 387 936
Age (yr) 59.4±9.7 60.4±10.3 0.110
Male sex 285 (73.6) 541 (63.6) 0.001
Family history of CRC (%)  6.6  4.4 0.120
Smoking (%) 35.3 26.8 0.004
Alcohol (%) 42.7 33.0 0.002
Hypertension (%) 24.7 21.0 0.320
Diabetes mellitus (%)  5.2 5.4 0.910
Aspirin/NSAIDs use (%) 12.3 10.8 0.610
Statin use (%)  4.9 4.5 0.850
Baseline adenoma character
   Number ≥3 126 (32.6) 260 (27.8) 0.080
   Size ≥10 mm  90 (23.3) 175 (18.7) 0.060
   Villous histology  62 (16.0) 107 (11.4) 0.020
   High grade dysplasia 33 (8.5) 59 (6.3) 0.160
   Advanced adenoma 133 (34.4) 241 (25.7) 0.002
Values are presented as mean±SD or number (%).
CRC, colorectal cancer.
Table 2. Univariate and Multivariate Analyses on RR of Baseline 
Demographic Characteristics for Recurrent Advanced Adenoma 
Baseline 
demographic 
characteristics
Advanced 
adenoma
Univariate OR 
(95% CI)
Multivariate OR 
(95% CI) P-value
Sex
   Female 0/102 (0) 1.0
   Male 17/285 (6.0) 1.06 (1.03–1.10) NA NA
Age (yr)
   <50  0/63 (0) 1.0
   ≥50 17/324 (5.2) 1.06 (1.03–1.08) NA NA
Smoking
   (–) 11/235 (4.7) 1.0
   (+) 6/128 (4.7) 1.00 (0.36–2.77) 0.64 (0.16–2.66) 0.54
Alcohol
   (–) 9/207 (4.3) 1.0
   (+) 8/154 (5.2) 1.21 (0.45–3.20) 1.66 (0.44–6.32) 0.46
Family history
   (–) 15/341 (4.4) 1.0
   (+)  2/24 (8.3) 1.98 (0.43–9.19) 0.82 (0.10–6.54) 0.85
Hypertension
   (–) 12/247 (4.9) 1.0 
   (+) 3/81 (3.7) 0.75 (0.21–2.74) 0.91 (0.22–3.81) 0.90
Diabetes mellitus
   (–) 14/311 (4.5) 1.0
   (+)   1/17 (5.9) 1.33 (0.16–10.72) 1.51 (0.18–12.81) 0.71
Aspirin/NSAIDs
   (–) 15/307 (4.9) 1.0
   (+)   2/43 (4.7) 0.95 (0.21–4.30) 0.62 (0.06–5.98) 0.68
Statins
   (–) 17/333 (5.1) 1.0
   (+) 0/17 (0) NA NA
Values are presented as number/number (%).
NA, not applicable.
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2. Incidence and Risk Factors of Recurrence of 
Colorectal Adenoma
During the follow-up period of 31.0±9.8 months, the recur-
rence rates of advanced adenoma, multiple adenoma with 
3 or more, and any adenoma were 4.4% (17/387), 10.6% 
(41/387), and 48.3% (187/387), respectively.
Tables 2 and 3 demonstrate the RR of demographic and 
baseline adenoma characteristics for recurrent advanced 
adenoma after multivariate adjustments. Among the de-
mographic variables, advanced adenoma recurrence was 
observed only in males and in subjects aged ≥50 years at 
follow-up (Table 2). On the contrary, there was no significant 
risk factor for advanced adenoma recurrence among the 
baseline adenoma variables. However, the risk of advanced 
adenoma recurrence was 2 times higher in patients with 
baseline advanced adenoma than in patients with baseline 
non-advanced adenoma, though the difference was not sta-
tistically significant (6.8% [9/133] vs. 3.1% [8/254], P =0.09] 
(Table 3).
Tables 4 and 5 present the RR associated with each of 
the demographic and baseline adenoma characteristics for 
recurrent overall colorectal adenoma and multiple (≥3) ad-
enomas, respectively. Male sex, age ≥50 years, and number 
of adenomas (≥3) had a significant impact on both overall 
adenoma recurrence and multiple (≥3) colorectal adenoma 
recurrence after multivariate adjustments.
Table 4. Multivariate Analyses on RR of Baseline Adenoma 
Characteristics for Any Type of Recurrent Colorectal Adenoma
Adjusted OR (95% CI) P-value
Baseline characteristics
   Sex
      Female 1.0
      Male 1.78 (1.10–2.87) 0.02
   Age (yr)
      <50 1.0
      ≥50 2.02 (1.12–3.65) 0.02
Baseline adenoma characteristics
   Number
      1 or 2 1.0
      ≥3 2.43 (1.54–3.83) 0.00
   Size (mm)
      <10 1.0
      ≥10 0.96 (0.58–1.58) 0.86
   Type
      Tubular 1.0
      TVA or VA 0.98 (0.54–1.78) 0.95
   Dysplasia
      Low-grade 1.0
      High-grade 1.07 (0.49–2.34) 0.87
   AA
      (–) 1.0
      (+) 1.14 (0.73–1.78) 0.57
TVA, tubulovillous adenoma; VA, villous adenoma; AA, advanced 
adenoma.
Table 3. Univariate and Multivariate Analyses on RR of Baseline 
Adenoma Characteristics for Recurrent Advanced Adenoma
Baseline 
demographic 
characteristics
Advanced 
adenoma
Univariate OR 
(95% CI)
Multivariate OR 
(95% CI) P-value
Number
   1 or 2 10/261 (3.8) 1.0
   ≥3 7/126 (5.6) 1.48 (0.55–3.97) 1.93 (0.49–7.57) 0.35
Size (mm)
   <10 11/297 (3.7) 1.0
   ≥10 6/90 (6.7) 1.86 (0.67–5.17) 0.88 (0.16–4.96) 0.88
Type
   Tubular 13/325 (4.0) 1.0
   TVA or VA 4/62 (6.5) 1.66 (0.52–5.25) 0.85 (0.17–4.30) 0.84
Dysplasia
   Low-grade 15/354 (4.2) 1.0
   High-grade 2/33 (6.1) 1.46 (0.32–6.67) 0.83 (0.16–4.41) 0.83
Location
   Left 9/195 (4.6) 1.0
   Right 8/192 (4.2) 0.90 (0.34–2.38) 0.97 (0.36–2.63) 0.96
AA
   (–) 8/254 (3.1) 1.0
   (+) 9/133 (6.8) 2.23 (0.84–5.93) 4.38 (0.39–49.62) 0.23
AA/number
   Non-AA & <3 6/182 (3.3) 1.0
   AA or ≥3 11/205 (5.4) 1.67 (0.60–4.59) 0.44 (0.05–3.64) 0.44
Values are presented as number/number (%).
TVA, tubulovillous adenoma; VA, villous adenoma; AA, advanced 
adenoma.
Won Seok Choi, et al. • Colonoscopy surveillance after polypectomy
130 www.irjournal.org
DISCUSSION
In the present multicenter, prospective study, the 3-year 
cumulative incidence rate of advanced adenoma in Korean 
patients with colorectal adenoma at the baseline screening 
colonoscopy was 4.4%. The risk of advanced adenoma recur-
rence was 2 times higher in patients with baseline advanced 
adenoma than in patients with baseline non-advanced ad-
enoma. Advanced adenoma recurrence was observed only 
in males and subjects aged ≥50 years at follow-up. In addi-
tion, male sex, older age (≥50 years), and multiple adenomas 
(≥3) were independent risk factors for overall adenoma and 
multiple adenoma recurrence.
According to the official reports of Korea Central Cancer 
Registry, the incidence rates for CRC have continued to in-
crease over the past 14 years (1999–2012) in Korea because 
of the spread of the Westernized lifestyle, particularly in 
terms of dietary habits.10,11 CRC was the second most com-
mon cancer in males, the third most common in females, 
and the fourth cause of cancer deaths in 2012 in Korea.12,13 
Screening colonoscopy and polypectomy are important to 
reduce the incidence and mortality of CRC.14 Patients with 
removed adenomas are advised to have follow-up surveil-
lance colonoscopy according to risk stratification based on 
the findings at baseline colonoscopy. However, few studies 
have been conducted on follow-up surveillance colonoscopy 
after polypectomy in Asia.
Patients with baseline adenoma are considered at higher 
risk of colorectal neoplasia, even after their polyps have been 
removed.4,15-17 Recurrent adenomas of any kind were found 
in about 20% to 49% of patients who underwent follow-up 
colonoscopy within 3 to 5 years after polypectomy in sev-
eral Western population-based studies,15,18-22 and advanced 
adenomas were detected in 6% to 13% of these patients. In a 
Chinese population-based study, the cumulative recurrence 
rates of any adenoma and of advanced adenoma were 21.1% 
and 2.2%, respectively, during the surveillance interval of 1 to 
3 years after polypectomy.23 One Japanese multicenter retro-
spective study has reported the 3-year cumulative incidence 
of large adenomatous polyps ≥10 mm, intramucosal cancer, 
and invasive cancer to be 3.9% after polypectomy.24 In Korea, 
a prospective study has reported recurrent adenoma rates 
of about 33.3% within 3 years after polypectomy, with about 
6.6% of recurrences being advanced adenoma.3 In the present 
study, the 3-year recurrence rates of any adenoma (48.3%) 
and advanced adenoma (4.4%) were similar to those studies.
We also investigated the risk factors for adenoma recur-
rence in all patients who underwent surveillance colonos-
copy. Although a few studies have supported the effects of 
age,15,21,25 gender,22,24,26 family history,27,28 obesity,29,30 smok-
ing,31,32 and aspirin/NSAID33 or statin use34 on adenomas, 
the issue remains controversial. The Asia Pacific Working 
Group reported that advancing age, male sex, family history, 
and smoking are the most important risk factors for devel-
oping advanced CRC.13 A report from a pooled analysis of 
postpolypectomy patients showed that older age and male 
sex were associated with an increased risk of metachronous 
advanced adenoma.21 One Japanese study24 and one Chi-
nese study23 also reported that the occurrence of advanced 
neoplasia at surveillance colonoscopy was associated with 
the male sex and older age, while another Chinese study25 
reported that older age alone was an important risk factor 
for advanced neoplasia recurrence. Several previous studies 
Table 5. Multivariate Analyses on RR of Baseline Adenoma 
Characteristics for Recurrent Multiple Adenoma
Adjusted OR (95% CI) P-value
Baseline characteristics
   Sex
      Female 1.0
      Male 8.09 (1.02–64.08) 0.05
   Age (yr)
      <50 1.0
      ≥50 11.67 (1.39–97.80) 0.02
Baseline adenoma characteristics
   Number
      1 or 2 1.0
      ≥3 2.60 (1.34–5.04) 0.01
   Size (mm)
      <10 1.0
      ≥10 0.87 (0.38–2.03) 0.75
   Type
      Tubular 1.0
      TVA or VA 0.62 (0.20–1.87) 0.39
   Dysplasia
      Low-grade 1.0
      High-grade 0.27 (0.03–2.11) 0.21
   AA
      (–) 1.0
      (+) 0.61 (0.25–1.51) 0.29
TVA, tubulovillous adenoma; VA, villous adenoma; AA, advanced 
adenoma.
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suggested that males have a higher prevalence of advanced 
adenoma than females during surveillance colonoscopy.22,26 
In this prospective study, we confirmed that the male sex 
and age ≥50 years had a significant effect on the recurrence 
of any adenoma, multiple adenomas, and advanced adeno-
ma. In the multivariate analysis, family history, smoking, and 
medication were not associated with advanced adenoma 
recurrence. However, the low rate of patients who underwent 
surveillance colonoscopy and the low incidence of advanced 
adenoma on follow-up may have contributed to the negative 
results.
A number of studies have reported that the size, number, 
and histological characteristics of the baseline adenoma 
were associated with an increased risk of advanced ad-
enoma recurrence.4,21,25,27,35 Some studies have demonstrated 
recurrence rates of advanced adenoma at 3-year follow-up 
after polypectomy of 5% to 17% for adenomas larger than 1 
cm,4,15,22,36 10% to 13% for villous adenomas,4,22,36 10% to 12% 
for adenomas with high grade dysplasia,4,36 and 9% to 18% 
for 3 or more adenomas.15,22,36 In the latest U.S. guidelines, pa-
tients with advanced adenoma or 3 or more adenomas are 
recommended to have follow-up surveillance colonoscopy 
at 3 years.7 In this study, despite the lack of statistical signifi-
cance, the risk of advanced adenoma recurrence was 2 times 
higher in patients with baseline advanced adenoma than in 
patients with baseline non-advanced adenoma, confirming 
the definitive difference in advanced adenoma recurrence 
at the 3-year follow-up between patients with baseline ad-
vanced adenoma and patients without baseline advanced 
adenoma. Our study also showed that the presence of 3 or 
more adenomas at baseline was an independent risk factor 
for overall adenoma recurrence, confirming that the number 
of adenomas at baseline colonoscopy should be considered 
in determining the interval of surveillance colonoscopy. We 
were unable to find any relationship between other baseline 
adenoma characteristics such as size, histology, and degree 
of dysplasia and advanced adenoma recurrence, which may 
be due to the small number of patients in this study who ex-
perienced advanced adenoma recurrence.
Prior reports have shown that an increased risk of ad-
vanced adenoma is associated with baseline advanced ade-
noma.3,15,22-27 Nusko et al.27 demonstrated that the recurrence 
rates of advanced adenoma after polypectomy were 10% at 3 
years. In Korean patients with baseline advanced adenoma, 
Seo et al.37 reported that the 3-year cumulative rates of meta-
chronous advanced neoplasm were 13.2%, while Chung et 
al.3 reported that the 5-year cumulative rates of advanced 
adenoma were 12.2%. A pooled analysis that used individual 
data from 8 North American prospective studies also indi-
cated that patients with baseline advanced adenoma were 
more likely to develop advanced neoplasm (15.5%) after a 
median of 4 years of follow-up surveillance.21 Thus, interna-
tional guidelines such as the U.S. Multi-Society Task Force on 
Colorectal Cancer,7 American College of Gastroenterology, 
American Society of Gastrointestinal Endoscopy, and British 
Society of Gastroenterology38 have recommended follow-up 
colonoscopy at 3 years after polypectomy in patients with 
baseline advanced adenoma.5 In the present study, 3-year 
cumulative recurrence rate of advanced adenoma was low 
(6.8%) in patients with baseline advanced adenoma; there-
fore, our results indicate that the current recommendation 
of 3-year follow-up surveillance colonoscopy after polypec-
tomy in patients with high-risk findings is appropriate.
Our study has several limitations. First, only 29.3% of pa-
tients had a surveillance colonoscopic examination during 
the follow-up period, which may have introduced a possible 
selection bias. The surveillance group had higher propor-
tions of males, smokers, and alcohol drinkers and was more 
likely to have purported high CRC risk variables for baseline 
adenoma, including advanced adenoma, number, size, and 
villous histology in comparison with the non-surveillance 
group. We had considered that the surveillance group in our 
study might have a higher risk potential for advanced ad-
enoma recurrence compared with the baseline enrolled pa-
tients. Second, this was not a community-based cohort study 
because our population was derived from a group of tertiary 
medical centers. Therefore, a selection bias could not be 
avoided. Third, we were unable to evaluate other risk factors 
for colorectal neoplasia after polypectomy, such as obesity, 
BMI, metabolic syndrome, diet, and physical activity, which 
may have influenced the recurrence rate of adenomas, and 
further studies aimed at assessing recurrence in the context 
of those factors are necessary.
In conclusion, the results of the present Korean prospec-
tive multicenter study reveal that a 3-year surveillance in-
terval for patients with baseline advanced adenoma can be 
considered appropriate. Future studies designed to evaluate 
the surveillance interval after polypectomy based on both 
stratified risk factors and cost-effectiveness are warranted in 
Korea.
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